Drugs / maxacalcitol
maxacalcitol
also known as
1alpha,25-dihydroxy-22-oxavitamin d3 · 22-oxacalcitriol · Oxarol · Prezios · SCH 209579
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00667576 | Apr 2008 → Mar 2009 | chronic kidney disease, secondary hyperparathyroidism of renal origin | Abbott | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00990704 Comparator | Oct 2009 → May 2010 | secondary hyperparathyroidism of renal origin | Abbott | Completed | Missed primary |
| Phase 3 | NCT01341782 Comparator | May 2011 → Apr 2012 | secondary hyperparathyroidism | AbbVie | Completed | No outcome recorded |
Press releases naming this drug 4 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | maxacalcitol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00990704 ↗ |
| Known as | 1alpha,25-dihydroxy-22-oxavitamin d3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL333950 ↗ |
| Known as | 22-oxacalcitriol | ChEMBL registry synonym — accepted as the source's own label CHEMBL333950 ↗ |
| Known as | Oxarol | ChEMBL registry synonym — accepted as the source's own label CHEMBL333950 ↗ |
| Known as | Prezios | ChEMBL registry synonym — accepted as the source's own label CHEMBL333950 ↗ |
| Known as | SCH 209579 | ChEMBL registry synonym — accepted as the source's own label CHEMBL333950 ↗ |
| Modality | Small molecule | — CHEMBL333950 ↗ |
| Route | Intravenous | “Intravenous administration 3 times a week immediately before completion of dialysis” NCT00990704 ↗ |